Rs401681 and rs402710 polymorphisms of CLPTM1L gene in cancerous and healthy lung tissues in patients with lung adenocarcinoma

• Authors: Joanna Żywiec , Mateusz Rydel , Bogna Drozdzowska , Katarzyna Klimczyk , Janusz Kasperczyk , Damian Czyżewski

Title variants

PL

Polimorfizmy rs401681 i rs402710 genu CLPTM1L w tkance zmienionej nowotworowo i w tkance zdrowej płuc u chorych z gruczolakorakiem płuca

• Languages of publication: EN PL

Abstracts

EN

INTRODUCTION: The search for factors influencing the survival of patients with lung cancer is still ongoing. It may potentially be a polymorphism of the cleft lip and palate transmembrane 1-like (CLPTM1L) gene, which is involved in the process of carcinogenesis. The aim of the study was to assess the distribution of genotypes and alleles of selected polymorphisms of the CLPTM1L gene – rs401681 and rs402710 – in cancerous and healthy lung tissue in patients with lung adenocarcinoma and their relationship with patient survival. MATERIAL AND METHODS: The study included 133 patients with an average age of lung cancer diagnosis of 65 years, who had undergone lung adenocarcinoma surgery in the past. Genetic material – deoxyribonucleic acid (DNA) – was isolated from paraffin-protected specimens of cancerous and healthy lung tissue, and genotyping of CLPTM1L polymorphisms was performed. The obtained results were analyzed along with demographic data, history of smoking, family history of cancer, stage of the disease in the tumor, node, metastasis (TNM) classification, clinical stage of the cancer and the survival time of the patients. RESULTS: The mean follow-up period was 44.5 months. The patients who died lived an average of 22.6 months from the time of cancer diagnosis. There were no significant differences between the distribution of genotypes or alleles in the cancerous and healthy tissues and their relationship with the survival of the patients. The age at the time of diagnosis of cancer, category N in the TNM classification and high clinical advancement of the cancer were the only factors influencing the survival of the patients. CONCLUSIONS: No relationships between the polymorphic variability of rs401681 and rs402710 in cancerous and healthy lung tissue and the survival of patients were found.

PL

WSTĘP: Poszukiwanie czynników wpływających na przeżycie chorych z nowotworami płuc jest stale aktualne. Takim potencjalnym czynnikiem jest polimorfizm genu CLPTM1L (cleft lip and palate transmembrane 1-like), włączony w proces karcynogenezy. Celem pracy była ocena rozkładu genotypów i alleli wybranych polimorfi-zmów genu CLPTM1L – rs401681 i rs402710 – w tkance zmienionej nowotworowo i w tkance zdrowej płuc u chorych z gruczolakorakiem płuca oraz ich związku z przeżyciem chorych. MATERIAŁ I METODY: Badaniami objęto 133 chorych w wieku ujawnienia nowotworu płuca wynoszącym średnio 65 lat, u których w przeszłości dokonano usunięcia gruczolakoraka płuc. Z zabezpieczonych w parafi-nie próbek tkanki zdrowej płuc i z tkanki zmienionej chorobowo wyizolowano materiał genetyczny – kwas deoksyrybonukleinowy (DNA) – oraz przeprowadzono genotypowanie polimorfizmów CLPTM1L. Uzyskane wyniki poddano analizie wraz z danymi demograficznymi, wywiadem dotyczącym palenia tytoniu, wywiadem rodzinnym obciążonym nowotworowo, stadium choroby w klasyfikacji TNM (tumor, node, metastasis), za-awansowaniem klinicznym nowotworu i czasem przeżycia chorych. WYNIKI: Średni czas obserwacji wynosił 44,5 miesiąca. Chorzy, którzy zmarli, żyli średnio 22,6 miesiąca od czasu postawienia diagnozy nowotworu. Nie stwierdzono znamiennych różnic pomiędzy rozkładem genotypów ani alleli w tkankach chorej i zdrowej płuc oraz ich związku z przeżyciem chorych. Czynnikami wpływającymi na przeżycie chorych były wiek w czasie postawienia diagnozy nowotworu, kategoria N w klasyfikacji TNM oraz wysokie zaawansowanie kliniczne nowotworu. WNIOSKI: Nie stwierdzono związku pomiędzy zmiennością polimorficzną rs401681 i rs402710 w tkance chorej i zdrowej płuc a przeżyciem chorych.

Keywords

EN

CLPTM1L gene; analiza przeżycia; gen CLPTM1L; gruczolakorak płuca; lung adenocarcinoma; rs401681; rs402710; survival analysis

Discipline

• MEDICINE: MEDICINE

• Publisher: Śląski Uniwersytet Medyczny w Katowicach
• Journal: Annales Academiae Medicae Silesiensis
• Year: 2023
• Issue: 77
• Pages: 166–175

Contributors

author

Joanna Żywiec

• Department of Clinical Pharmacology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland / Zakład Farmakologii Klinicznej, Wydział Nauk Medycznych w Zabrzu, Śląski Uniwersytet Medyczny w Katowicach

author

Mateusz Rydel

• Department of Thoracic Surgery, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland / Kate-dra i Klinika Chirurgii Klatki Piersiowej, Wydział Nauk Medycznych w Zabrzu, Śląski Uniwersytet Medyczny w Katowicach

author

Bogna Drozdzowska

• Department of Pathomorphology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland / Kate-dra i Zakład Patomorfologii, Wydział Nauk Medycznych w Zabrzu, Śląski Uniwersytet Medyczny w Katowicach

author

Katarzyna Klimczyk

• Department of Internal Medicine, Diabetology and Nephrology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland / Katedra Chorób Wewnętrznych, Diabetologii i Nefrologii, Wydział Nauk Medycznych w Zabrzu, Śląski Uniwersytet Medyczny w Katowicach

author

Janusz Kasperczyk

• Department of Environmental Medicine and Epidemiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland / Katedra i Zakład Medycyny i Epidemiologii Środowiskowej, Wydział Nauk Medycznych w Zabrzu, Śląski Uniwersytet Medyczny w Katowicach

author

Damian Czyżewski

• Department of Thoracic Surgery, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland / Kate-dra i Klinika Chirurgii Klatki Piersiowej, Wydział Nauk Medycznych w Zabrzu, Śląski Uniwersytet Medyczny w Katowicach

References

• 1. Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C. et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase. No. 11. Lyon, France: International Agency for Research on Cancer 2013; [online] http://globocan.iarc.fr/577 [accessed on 15 September 2023].
• 2. Allemani C., Weir H.K., Carreira H., Harewood R., Spika D., Wang X.S. et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2015; 385(9972): 977−1010, doi: 10.1016/S0140-6736(14)62038-9.
• 3. Thun M.J., Henley S.J., Burns D., Jemal A., Shanks T.G., Calle E.E. Lung cancer death rates in lifelong nonsmokers. J. Natl. Cancer Inst. 2006; 98(10): 691−699, doi: 10.1093/jnci/djj187.
• 4. Couraud S., Souquet P.J., Paris C., Dô P., Doubre H., Pichon E. et al. BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers. Eur. Respir. J. 2015; 45(5): 1403–1414, doi: 10.1183/09031936.00097214.
• 5. Lebrett M.B., Crosbie E.J., Smith M.J., Woodward E.R., Evans D.G., Crosbie P.A.J. Targeting lung cancer screening to individuals at greatest risk: the role of genetic factors. J. Med. Genet. 2021; 58(4): 217−226, doi: 10.1136/jmedgenet-2020-107399.
• 6. Wang J., Liu Q., Yuan S., Xie W., Liu Y., Xiang Y. et al. Genetic predisposition to lung cancer: comprehensive literature integration, meta--analysis, and multiple evidence assessment of candidate-gene association studies. Sci. Rep. 2017; 7(1): 8371, doi: 10.1038/s41598-017-07737-0.
• 7. Zhang X., Sjöblom T. Targeting loss of heterozygosity: A novel para-digm for cancer therapy. Pharmaceuticals (Basel). 2021; 14(1): 57, doi: 10.3390/ph14010057.
• 8. Mendes-da-Silva P., Moreira A., Duro-da-Costa J., Matias D., Monteiro C. Frequent loss of heterozygosity on chromosome 5 in non-small cell lung carcinoma. Mol. Pathol. 2000; 53(4): 184−187, doi: 10.1136/mp.53.4.184.
• 9. Yoshino I., Osoegawa A., Yohena T., Kameyama T., Oki E., Oda S. et al. Loss of heterozygosity (LOH) in non-small cell lung cancer: difference between adenocarcinoma and squamous cell carcinoma. Respir. Med. 2005; 99(3): 308−312, doi: 10.1016/j.rmed.2004.08.008.
• 10. Liu C., Cui H., Gu D., Zhang M., Fang Y., Chen S. et al. Genetic polymorphisms and lung cancer risk: Evidence from meta-analyses and genome-wide association studies. Lung Cancer 2017; 113: 18−29, doi: 10.1016/j.lungcan.2017.08.026.
• 11. Xun X., Wang H., Yang H., Wang H., Wang B., Kang L. et al. CLPTM1L genetic polymorphisms and interaction with smoking and alcohol drinking in lung cancer risk: a case-control study in the Han population from northwest China. Medicine (Baltimore) 2014; 93(28): e289, doi: 10.1097/MD.0000000000000289.
• 12. Tian J., Wang Y., Dong Y., Chang J., Wu Y., Chang S. et al. Cumulative evidence for relationships between multiple variants in the TERT and CLPTM1L region and risk of cancer and non-cancer disease. Front. Oncol. 2022; 12: 946039, doi: 10.3389/fonc.2022.946039.
• 13. Yamamoto K., Okamoto A., Isonishi S., Ochiai K., Ohtake Y. A novel gene, CRR9, which was up-regulated in CDDP-resistant ovarian tumor cell line, was associated with apoptosis. Biochem. Biophys. Res. Commun. 2001; 280(4): 1148−1154, doi: 10.1006/bbrc.2001.4250.
• 14. Zhang R., Shen S., Wei Y., Zhu Y., Li Y., Chen J. et al. A large-scale genome-wide gene-gene interaction study of lung cancer susceptibility in Europeans with a trans-ethnic validation in Asians. J. Thorac. Oncol. 2022; 17(8): 974−990, doi: 10.1016/j.jtho.2022.04.011.
• 15. Lim W., Ridge C.A., Nicholson A.G., Mirsadraee S. The 8th lung cancer TNM classification and clinical staging system: review of the changes and clinical implications. Quant. Imaging Med. Surg. 2018; 8(7): 709−718, doi: 10.21037/qims.2018.08.02.
• 16. Hou Y., Xue F., Fu Y., Feng G., Wang R., Yuan H. CLPTM1L is a novel putative oncogene promoting tumorigenesis in oral squamous cell carcino-ma. Cell Transplant. 2021; 30: 9636897211045970, doi: 10.1177/09636897211045970.
• 17. Zienolddiny S., Skaug V., Landvik N.E., Ryberg D., Phillips D.H., Houlston R. et al. The TERT-CLPTM1L lung cancer susceptibility variant associates with higher DNA adduct formation in the lung. Carcinogenesis 2009; 30(8): 1368−1371, doi: 10.1093/carcin/bgp131.
• 18. Ni Z., Chen Q., Lai Y., Wang Z., Sun L., Luo X. et al. Prognostic significance of CLPTM1L expression and its effects on migration and invasion of human lung cancer cells. Cancer Biomark. 2016; 16(3): 445−452, doi: 10.3233/CBM-160583.
• 19. James M.A., Wen W., Wang Y., Byers L.A., Heymach J.V., Coombes K.R. et al. Functional characterization of CLPTM1L as a lung cancer risk candidate gene in the 5p15.33 locus. PLoS One 2012; 7(6): e36116, doi: 10.1371/journal.pone.0036116.
• 20. Ni Z., Tao K., Chen G., Chen Q., Tang J., Luo X. et al. CLPTM1L is overexpressed in lung cancer and associated with apoptosis. PLoS One 2012; 7(12): e52598, doi: 10.1371/journal.pone.0052598.
• 21. Li H., Che J., Jiang M., Cui M., Feng G., Dong J. et al. CLPTM1L induces estrogen receptor β signaling-mediated radioresistance in non-small cell lung cancer cells. Cell Commun. Signal. 2020; 18(1): 152, doi: 10.1186/s12964-020-00571-4.
• 22. Li C., Yin Z., Wu W., Li X., Zhou B. Genetic variants in TERT-CLPTM1L genetic region associated with several types of cancer: a meta-analysis. Gene 2013; 526(2): 390−399, doi: 10.1016/j.gene.2013.05.003.
• 23. Yang Y.C., Fu W.P., Zhang J., Zhong L., Cai S.X., Sun C. rs401681 and rs402710 confer lung cancer susceptibility by regulating TERT expression instead of CLPTM1L in East Asian populations. Carcinogenesis 2018; 39(10): 1216−1221, doi: 10.1093/carcin/bgy084.
• 24. Zhao D.P., Yang C.L., Zhou X., Ding J.A., Jiang G.N. Association between CLPTM1L polymorphisms (rs402710 and rs401681) and lung cancer susceptibility: evidence from 27 case-control studies. Mol. Genet. Genomics 2014; 289(5): 1001−1012, doi: 10.1007/s00438-014-0868-7.
• 25. Zhang X.L., Zhang X.J., Zhang Y.M., Zhang Q., Cao C.X., Gu D.Y. et al. Decreased risk of developing lung cancer in subjects carrying the CLPTM1L rs401681 (G>A) polymorphism: evidence from a meta-analysis. Genet. Mol. Res. 2014; 13(1): 1373−1382, doi: 10.4238/2014.February.28.10.
• 26. Tang J., Hu C., Mei H., Peng L., Li H. CLPTM1L gene rs402710 (C > T) and rs401681 (C > T) polymorphisms associate with decreased cancer risk: a meta-analysis. Oncotarget 2017; 8(60): 102446−102457, doi: 10.18632/oncotarget.22268.
• 27. Chen X.F., Cai S., Chen Q.G., Ni Z.H., Tang J.H., Xu D.W. Multiple variants of TERT and CLPTM1L constitute risk factors for lung adenocarcinoma. Genet. Mol. Res. 2012; 11(1): 370–378, doi: 10.4238/2012.February.16.2.

• Document Type: article